$5,999.00 – $9,699.00
Phesgo is the first oncology drug to be a ready-to-use, fixed-dose combination of two HER2-targeted monoclonal antibodies, pertuzumab and trastuzumab, administered by subcutaneous injection over approximately 5-8 minutes.
The drug contains the same antibodies as those found in intravenous dosage forms and is a fixed-dose combination. Indications for the fixed combination are similar to those of pertuzumab and include both early and metastatic HER2-positive breast cancer.
The drug is indicated for use in combination with chemotherapy:
as neoadjuvant therapy in adult patients with HER2-positive locally advanced, edematous-infiltrative or early breast cancer with a high risk of relapse;
as adjuvant therapy in adult patients with HER2-positive early breast cancer at high risk of recurrence.
Fesgo is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent, unresectable breast cancer who have not received prior HER2-specific therapy or chemotherapy for metastatic disease.
Active substance: pertuzumab + trastuzumab
Prescription medicine
Storage temperature 2-8 degrees
‘
| Дозировка | 600 Mg, 1200 Mg |
|---|
